Profectus BioSciences, a Baltimore, Md., developer of antiviral drugs and vaccines targeting HIV, raised $3 million in a private placement. Private investors, including Cross Atlantic Capital Partners and board member Stewart Greenebaum, contributed.

Profectus is developing ways to combine AIDS drugs with “immune modulators” that would render HIV more vulnerable to antiviral attack, and is also at work on an AIDS vaccine. The company was founded in 2003 by three eminent virologists who also co-founded the Institute for Human Virology in Baltimore: Robert Gallo, William Blattner and Robert Redfield.